Complex Event Analysis - Report

Complex Event Analysis - REPORT

Supporting narratives:

• challenge (Read more)
• The British-Swedish pharmaceutical giant is aiming to produce 2 billion doses of the vaccine, with a view to roll 400 million doses out to the U.S. by October.
  AstraZeneca's vaccine has also received multimillion dollar investments from the U.K. government and a $843 million payment from some EU countries, who have secured access to the vaccine should it prove to be effective.
  Meanwhile, the Canadian government's National Research Council has signed a deal with China's CanSino Biologics to manufacture its vaccine for clinical trials in Canada this summer
• High Level Abstractions:
• (investments,vaccine)

• challenge (Read more)
• "Non-profits have put frameworks in place to try and ease this burden, but it's something we as an industry need to address head on."
  Raveendran noted that while the stockpiling of Covid-19 vaccines would make developing them a commercially viable endeavour, it could come at a cost to public health.
  "If we resolve the situation in developed markets and there's still virus running rampant in other parts of the world, this is a problem for all of us," she told CNBC. "We need to be very aware of how we distribute a very limited resource at the beginning."
  Goldin added that if the virus mutated in parts of the world that were unable to access the vaccine, Covid-19 would once again pose a threat to global public health, even for those who were immunized.
  "We don't know how long these vaccines will last and how effective they'll be," he said
• High Level Abstractions:
• (covid-19,vaccine)
• (health,vaccine)
• (vaccine,virus)
• (vaccine,vaccines)
• (threat,vaccine)
• Inferred entity relationships (4)

  (covid-19,vaccine,wuhan) [inferred]

  (vaccine,vaccines,white_house) [inferred]

  (vaccine,virus,worldwide) [inferred]

  (covid-19,vaccine,zaks) [inferred]

• challenge (Read more)
• The British-Swedish pharmaceutical giant is aiming to produce 2 billion doses of the vaccine, with a view to roll 400 million doses out to the U.S. by October.
  AstraZeneca's vaccine has also received multimillion dollar investments from the U.K. government and a $843 million payment from some EU countries, who have secured access to the vaccine should it prove to be effective.
  Meanwhile, the Canadian government's National Research Council has signed a deal with China's CanSino Biologics to manufacture its vaccine for clinical trials in Canada this summer.
• High Level Abstractions:
• (summer,vaccine)

• WIP (Read more)
• "Existing international institutions and agreements will struggle to minimize this 'vaccine nationalism.'"
  The research group argued that some governments were already attempting to seize first access through large-scale investments.
  "In the U.S., the Biomedical Advanced Research Development Authority (BARDA) has been spreading its investments across a number of vaccine candidates in an effort to reduce the financial risks for pharmaceutical firms and lock in priority access to a successful vaccine," the note's authors said.
  BARDA has financial interests in Moderna's candidate vaccine and has invested in early research being conducted by French firm Sanofi and Britain's GlaxoSmithKline.
  In May, the U.S. also invested $1 billion in AstraZeneca's potential vaccine, which is being developed by scientists at the University of Oxford
• High Level Abstractions:
• (investments,vaccine)
• (nationalism,vaccine)

• WIP (Read more)
• We're all in the same game, so it will happen."
  Likening the vaccine development landscape to the space race of the 20th century, Rountree warned that vast government investments would not miraculously pave the way to an effective vaccine.
  "Politicians can put aggressive timelines in, and it lends itself to putting a man on the moon," he said
• High Level Abstractions:
• (investments,vaccine)
• (race,vaccine)

• WIP (Read more)
• "Vaccine nationalism" is turning the search for a Covid-19 cure into an arms race, which will ultimately damage the economy and public health, experts have warned.
  Analysts at Eurasia Group speculated that tension over a vaccine would heat up over the summer, predicting a battle for access that will stretch into 2021 or 2022.
  "Countries rich and poor will engage in aggressive procurement efforts with significant political, economic and public health implications," they said in a note earlier this year
• High Level Abstractions:
• (summer,vaccine)
• (covid-19,vaccine)
• (health,vaccine)
• (race,vaccine)
• (nationalism,vaccine)
• Inferred entity relationships (2)

  (covid-19,vaccine,wuhan) [inferred]

  (covid-19,vaccine,zaks) [inferred]

• WIP (Read more)
• We're all in the same game, so it will happen."
  Likening the vaccine development landscape to the space race of the 20th century, Rountree warned that vast government investments would not miraculously pave the way to an effective vaccine.
  "Politicians can put aggressive timelines in, and it lends itself to putting a man on the moon," he said.
• High Level Abstractions:
• (timelines,vaccine)

• WIP (Read more)
• "Existing international institutions and agreements will struggle to minimize this 'vaccine nationalism.'"
  The research group argued that some governments were already attempting to seize first access through large-scale investments.
  "In the U.S., the Biomedical Advanced Research Development Authority (BARDA) has been spreading its investments across a number of vaccine candidates in an effort to reduce the financial risks for pharmaceutical firms and lock in priority access to a successful vaccine," the note's authors said.
  BARDA has financial interests in Moderna's candidate vaccine and has invested in early research being conducted by French firm Sanofi and Britain's GlaxoSmithKline.
  In May, the U.S. also invested $1 billion in AstraZeneca's potential vaccine, which is being developed by scientists at the University of Oxford.
• High Level Abstractions:
• (scientists,vaccine)

Target rule match count: 15.0 Challenge: 0.22 Momentum: 0.00 WIP: 0.28